Search results
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 2 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 2 days agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 4 days agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Lifted by Hsbc Holdings PLC
ETF DAILY NEWS· 7 days agoHsbc Holdings PLC raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.7% during the fourth quarter, according to its most recent Form 13F filing with the ...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 3 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC Universal via AOL· 5 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 4 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 | The Motley Fool
The Motley Fool· 7 days agoAstraZeneca (AZN 1.24%), recognized as the world's sixth-largest pharmaceutical entity by market...